Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec082017	Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the APOLLO Read All »	View HTML Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer 86 KB
Toggle SummaryApr022019	Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment No Dose-Limiting Toxicities or Serious Adverse Events Reported following Three Once Weekly Doses of Universal, Off-the-Shelf NK Cell Product Candidate New Preclinical Data of Universal, Off-the-shelf, iPSC-derived NK Cell Product Candidates FT516 and FT596 Highlighted at 2019 AACR Annual Meeting Read All »	View HTML
Toggle SummaryJan052017	Fate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first patient has been treated in its PROTECT clinical trial Read All »	View HTML Fate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease 16.1 KB
Toggle SummaryApr022020	Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update SAN DIEGO , April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been treated in the Read All »	View HTML
Toggle SummaryJun202016	Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™ Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection Now Open for Enrollment Read All »	View HTML Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™ 16.4 KB
Toggle SummaryNov302018	Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting SAN DIEGO , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical Read All »	View HTML
Toggle SummaryJan262016	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection 16.8 KB
Toggle SummaryMar132017	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy 17.8 KB
Toggle SummaryMay102017	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors 17.6 KB
Toggle SummaryJul292014	Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders Phase 1b PROVIDE Study in Pediatric Patients with Inherited Metabolic Disorders Expected to Begin in 4Q14 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders 16.8 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.